{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:09Z","timestamp":1793045469490,"version":"4.5.0"},"reference-count":40,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ESGVH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The interplay between Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and viral hepatitis, primarily hepatitis B virus (HBV) and hepatitis C virus (HCV), presents a complex challenge in managing chronic liver diseases. Recent epidemiological insights suggest an escalating prevalence of MASLD globally, attributed mainly to the obesity epidemic and associated metabolic disorders. Concurrently, chronic viral hepatitis remains a significant contributor to liver disease morbidity and mortality worldwide, despite advances in antiviral therapies. According to the World Health Organization (WHO) 2023 data, approximately 296 million people are living with chronic HBV infection (about 3.8% of the global population), and 58 million people with HCV infection (about 0.7%), together accounting for over 1.1 million deaths annually. The coexistence of MASLD and viral hepatitis presents a complex scenario in clinical outcomes, where the effects on liver health can vary. Although many studies highlight the potential for additive or synergistic worsening of liver conditions, leading to complications such as cirrhosis, liver failure, and HCC, the impact of HBV on MASLD is not consistent. Managing patients with dual MASLD and viral hepatitis is complex due to the interplay of metabolic and viral factors. Lifestyle modifications, including weight loss, dietary changes, and physical activity, are fundamental to MASLD management and help reduce fibrosis risk in viral hepatitis. This review examines the dual impact of MASLD and viral hepatitis on liver pathology and delineates shared pathophysiological mechanisms, including the influence on hepatic steatosis, inflammation, and fibrogenesis. It also discusses therapeutic strategies tailored to manage this comorbidity, emphasizing the need for an integrated care approach that addresses both metabolic dysfunctions and viral infection to optimize patient outcomes.<\/jats:p>","DOI":"10.3390\/jcm14103422","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T08:44:58Z","timestamp":1747212298000},"page":"3422","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["When Metabolic Dysfunction-Associated Steatotic Liver Disease Meets Viral Hepatitis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6692-3893","authenticated-orcid":false,"given":"Imran","family":"Hasanoglu","sequence":"first","affiliation":[{"name":"Department of Infectious Disease and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara Bilkent City Hospital, Ankara 06800, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitario Reina Sofia, Instituto Maimonides de Investigaci\u00f3n Biom\u00e9dica de C\u00f3rdoba (IMIBIC), Universidad de C\u00f3rdoba (UCO), 14071 Cordoba, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CIBER) \u00c1rea de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8147-0068","authenticated-orcid":false,"given":"G\u00fcl\u015fen","family":"\u00d6zkaya \u015eahin","sequence":"additional","affiliation":[{"name":"Clinical Microbiology, Infection Prevention and Control, Office for Medical Services, 22467 Lund, Sweden"},{"name":"Division of Medical Microbiology, Department of Laboratory Medicine Lund, Medical Faculty, Lund University, 22467 Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESCMID Study Group for Viral Hepatitis (ESGVH)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Yang, Z., Li, A., Jiang, Y., Maidaiti, X., Wu, Y., and Jin, Y. (2024). Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease Attributable to High Fasting Plasma Glucose in 204 Countries and Territories from 1990 to 2021. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-72795-0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatol. Baltim. Md"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.3390\/clinpract14060200","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease in Chronic Hepatitis C Virus Infection: From Basics to Clinical and Nutritional Management","volume":"14","author":"Roman","year":"2024","journal-title":"Clin. Pract."},{"key":"ref_4","unstructured":"(2025, February 03). Hepatitis C. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.3748\/wjg.v27.i36.6025","article-title":"Hepatitis B Virus Infection and Hepatocellular Carcinoma in Sub-Saharan Africa: Implications for Elimination of Viral Hepatitis by 2030?","volume":"27","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_6","first-page":"128","article-title":"Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Viral Hepatitis","volume":"10","author":"Wang","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-Alcoholic Fatty Liver Disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.21037\/atm-21-3052","article-title":"Concurrence and Impact of Hepatic Steatosis on Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis","volume":"9","author":"Jiang","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/liv.15354","article-title":"The Changing Epidemiology of Liver Diseases in Asia","volume":"42","author":"Sun","year":"2022","journal-title":"Liver Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the Period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.cgh.2023.12.009","article-title":"Age, BMI, and Type 2 Diabetes Modify the Relationship Between PNPLA3 and Advanced Fibrosis in Children and Adults With NAFLD","volume":"22","author":"Jarasvaraparn","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Danpanichkul, P., Suparan, K., Kaeosri, C., Jatupornpakdee, P., Attia, A.M., Suenghataiphorn, T., Thongpiya, J., Sukphutanan, B., Huang, D.Q., and Noureddin, M. (2024). Global Trend of MASH-Associated Liver Cancer A Systematic Analysis from the Global Burden of Disease 2021. Clin. Gastroenterol. Hepatol., 16.","DOI":"10.1016\/j.cgh.2024.10.026"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e000025","DOI":"10.1136\/bmjgast-2014-000025","article-title":"The Societal Burden of Chronic Liver Diseases: Results from the COME Study","volume":"2","author":"Scalone","year":"2015","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.14218\/JCTH.2015.00051","article-title":"Hepatitis C Virus, Insulin Resistance, and Steatosis","volume":"4","author":"Kralj","year":"2016","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1743-7075-7-13","article-title":"Hepatic Steatosis in Hepatitis C Is a Storage Disease Due to HCV Interaction with Microsomal Triglyceride Transfer Protein (MTP)","volume":"7","author":"Mirandola","year":"2010","journal-title":"Nutr. Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2016.08.006","article-title":"Hepatitis B Virus (HBV) X Protein-Mediated Regulation of Hepatocyte Metabolic Pathways Affects Viral Replication","volume":"498","author":"Bagga","year":"2016","journal-title":"Virology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wu, Y., Ren, L., Mao, C., Shen, Z., Zhu, W., Su, Z., Lin, X., and Lin, X. (2024). Small Hepatitis B Virus Surface Antigen (SHBs) Induces Dyslipidemia by Suppressing Apolipoprotein-AII Expression through ER Stress-Mediated Modulation of HNF4\u03b1 and C\/EBP\u03b3. J. Virol., 98.","DOI":"10.1128\/jvi.01239-24"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The Role of Cholesterol in the Pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metab. TEM"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4239\/wjd.v5.i1.52","article-title":"Hepatitis C Virus Infection and Insulin Resistance","volume":"5","author":"Bose","year":"2014","journal-title":"World J. Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5014","DOI":"10.3748\/wjg.15.5014","article-title":"Steatosis and Insulin Resistance in Hepatitis C: A Way out for the Virus?","volume":"15","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.3748\/wjg.v22.i36.8161","article-title":"Impact of Hepatitis B Virus Infection on Hepatic Metabolic Signaling Pathway","volume":"22","author":"Shi","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cai, Q., Gan, C., Tang, C., Wu, H., and Gao, J. (2021). Mechanism and Therapeutic Opportunities of Histone Modifications in Chronic Liver Disease. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.784591"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jhep.2017.09.003","article-title":"Genetics and Epigenetics of NAFLD and NASH: Clinical Impact","volume":"68","author":"Eslam","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/jmv.25621","article-title":"The Impact of Hepatitis B Virus Infection Status on the Prevalence of Nonalcoholic Fatty Liver Disease: A Population-Based Study","volume":"92","author":"Huang","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.28917","article-title":"Hepatitis B Virus Infection and Decreased Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study","volume":"65","author":"Joo","year":"2017","journal-title":"Hepatol. Baltim. Md"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Somnay, K., Wadgaonkar, P., Sridhar, N., Roshni, P., Rao, N., and Wadgaonkar, R. (2024). Liver Fibrosis Leading to Cirrhosis: Basic Mechanisms and Clinical Perspectives. Biomedicines, 12.","DOI":"10.3390\/biomedicines12102229"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2014.04.026","article-title":"The Role of Kupffer Cells in Hepatitis B and Hepatitis C Virus Infections","volume":"61","author":"Boltjes","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated Mechanisms of MASLD Pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Zhao, L., Tang, H., and Cheng, Z. (2024). Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances. Pharmaceuticals, 17.","DOI":"10.3390\/ph17121724"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.cgh.2024.01.045","article-title":"Chronic Viral Hepatitis B and C Outweigh MASLD in the Associated Risk of Cirrhosis and HCC","volume":"22","author":"Lee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1111\/jvh.70004","article-title":"Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors","volume":"32","author":"Elgretli","year":"2025","journal-title":"J. Viral Hepat."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Lin, M., Gao, B., Peng, M., Chen, X., Xiao, H., Shi, M., Zhang, X., Zeng, F., and Chi, X. (2024). Metabolic Dysfunction-Associated Steatotic Liver Disease Increases Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Retrospective Cohort Study. Front. Physiol., 15.","DOI":"10.3389\/fphys.2024.1347459"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1007\/s10620-024-08354-4","article-title":"Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-Invasive Fibrosis Markers in Chronic Hepatitis B","volume":"69","author":"Con","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Meroni, M., Longo, M., and Dongiovanni, P. (2024). Cardiometabolic Risk Factors in MASLD Patients with HCC: The Other Side of the Coin. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1411706"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jhep.2016.07.037","article-title":"Host\u2014Hepatitis C Viral Interactions: The Role of Genetics","volume":"65","author":"Heim","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ali, H., Shahzil, M., Moond, V., Shahzad, M., Thandavaram, A., Sehar, A., Waseem, H., Siddiqui, T., Dahiya, D.S., and Patel, P. (2024). Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice. J. Pers. Med., 14.","DOI":"10.3390\/jpm14010061"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.cgh.2024.01.032","article-title":"The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis","volume":"22","author":"Abushamat","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and Efficacy of Combination Therapy with Semaglutide, Cilofexor and Firsocostat in Patients with Non-Alcoholic Steatohepatitis: A Randomised, Open-Label Phase II Trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1357633X231166032","article-title":"Hepatocellular Carcinoma Surveillance in the Telehealth Era: A Single-Centre Review","volume":"31","author":"Hui","year":"2025","journal-title":"J. Telemed. Telecare"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3422\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:32:27Z","timestamp":1760031147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14103422"],"URL":"https:\/\/doi.org\/10.3390\/jcm14103422","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]}}}